InvestorsHub Logo
icon url

Wo

06/25/18 4:52 PM

#79271 RE: TXBUYER #79270

The FDA ( US Agency ) is rescheduling Epidiolex specifically, although a derivative of CBD,

As part of the approval process, EPIDIOLEX must be rescheduled from its current Schedule I before it can be made available to patients. Rescheduling is expected to occur within 90 days. Access is expected to be similar to other branded AEDs and EPIDIOLEX is expected to be available to appropriate patients by Fall 2018. More information can be found at Epidiolex.com.

Outside the U.S., this medicine is currently under review by the European Medicines Agency (EMA) for the treatment of seizures associated with LGS and Dravet Syndrome. An EMA decision on whether to recommend approval is expected in the first quarter of 2019./quote]